CLAIMS

1. Use of VS-6063 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament, for treating a human subject suffering from cancer wherein VS-6063 or a pharmaceutically acceptable salt thereof is to be administered in combination with an anti-PD-1 antibody.

2. The use of claim 1, wherein the cancer is a solid tumor, soft tissue tumor, metastasis, or non-solid cancer.

3. The use of claim 2, wherein the cancer is solid tumor.

4. The use of claim 3, wherein the solid tumor is a malignancy (*e.g.*, sarcomas, adenocarcinomas, and carcinomas) of an organ (*e.g.*, of lung, breast, lymphoid, gastrointestinal (*e.g.*, colon), and genitourinary (*e.g.*, renal, urothelial, or testicular tumors) tracts, pharynx, prostate, and ovary).

5. The use of claim 1, wherein the cancer is a mesothelioma; neurofibromatosis(*e.g.*, neurofibromatosis type 2, neurofibromatosis type 1); renal cancer; lung cancer, non small cell lung cancer; liver cancer; pancreatic cancer; thyroid cancer; ovarian cancer; breast cancer; a nervous system tumor; schwannoma; meningioma; schwannomatosis; neuroma acoustic; adenoid cystic carcinoma; ependymoma; or ependymal tumors.

6. The use of claim 1, wherein the cancer is mesothelioma (*e.g.*, malignant pleural mesothelioma, (*e.g.*, surgical resectable malignant pleural mesothelioma)), breast cancer (*e.g.*, triple negative breast cancer), ovarian cancer (*e.g.*, advanced ovarian cancer), lung cancer (*e.g.*, non-small cell lung cancer (NSCLC) (*e.g.*, KRAS mutant NSCLC)), or a non-hematolotic malignancy.

7. The use of claim 1, wherein the cancer is melanoma (*e.g.*, N-Ras mutated locally advanced or metastasis malignant cutaneous melanoma), colorectal cancer (*e.g.*, metastatic colorectal cancer), leukemia (*e.g.*, acute myeloid leukemia), adenocarcinoma (*e.g.*, pancreatic adenocarcinoma), or a solid tumor (*e.g.*, locally advanced solid tumor, metastatic solid tumor, hepatocellular carcinoma).

8. The use of claim 1, wherein VS-6063 or a pharmaceutically acceptable salt thereof is to be administered orally.

9. The use of claim 8, wherein VS-6063 or a pharmaceutically acceptable salt thereof is to be administered at least once a day.

10. The use of claim 9, wherein VS-6063 or a pharmaceutically acceptable salt thereof is to be administered once a day.

11. The use of claim 9, wherein VS-6063 or a pharmaceutically acceptable salt thereof is to be administered twice a day.

12. The use of claim 8, wherein VS-6063 or a pharmaceutically acceptable salt thereof is to be administered at 100 mg to 2000 mg.

13. The use of claim 8, wherein VS-6063 or a pharmaceutically acceptable salt thereof is to be administered at 200 mg to 600 mg twice a day.

14. The use of claim 8, wherein VS-6063 or a pharmaceutically acceptable salt thereof is to be administered before or after (e.g., immediately before or immediately after) consumption of food.

15. The use of claim 1, wherein the anti-PD-1 antibody is to be administered parenterally.

16. The use of claim 15, wherein the anti-PD-1 antibody is anti-PD-1 or anti-PD-L1 (e.g., nivolumab (i.e., MDX-1106, BMS-936558, ONO-4538); CT-011; AMP-224; pembrolizumab; pidilizumab; or MK-3475)).

17. The use of claim 1, wherein the medicament is to be further adminsteredwith an additional chemotherapeutic agent or radiation therapy.

18. The use of claim 1, wherein the medicament is to be further administered with a cytotoxic agent.

19. The use of claim 18, wherein the cytotoxic agent is gemcitabine or paclitaxel (e.g., nab-paclitaxel).

20. The use of claim 1, wherein the medicament is to be further administered with an additional therapeutic agent selected from: Alkylating agents, Anti-metabolites, Antibiotics, Hormonal therapy agents, Plant derived anti-tumor substances, Cytotoxic topoisomerase inhibiting agents, Immunologicals, Biological response modifiers, Other anticancer agents, Other anti-angiogenic compounds, Platinum-coordinated compounds, Tyrosine kinase inhibitors, Antibodies, and Interferons.

21. The use of claim 1, wherein VS-6063 or a pharmaceutically acceptable salt thereof is to be administered before the anti-PD-1 antibody has been administered.

22. The use of claim 1, wherein VS-6063 or a pharmaceutically acceptable salt thereof is to be administered after the anti-PD-1 antibody has been administered.

23. The use of claim 1, wherein VS-6063 or a pharmaceutically acceptable salt thereof is to be administered concurrently with the anti-PD-1 antibody.

24. The use of claim 1, wherein the subject has been previously treated with a chemotherapeutic agent or with radiation therapy.

25. The use of claim 1, wherein the subject has failed (*e.g.*, relapsed from, insensitive to, received no or little benefit from) conventional or standard cancer treatment (*e.g.*, surgery, first-line therapy for cancer).

26. The use of claim 1, wherein the subject has failed (*e.g.*, relapsed from, insensitive to, received no or little benefit from) first-line treatment (*e.g.*, first-line therapy for cancer).

27. The use of claim 1, wherein the subject is identified to have high PD-L1 or PD-L2 (e.g., high PD-L1 or PD-L2) in tumor cells.

28. The use of claim 1, wherein the subject is identified to express interferon gamma-induced (IFN-γ) genes.